retatrutide cholesterol Retatrutide: A Promising Option for Non-Diabetic Weight Loss in Clinical Trials ✨ Big news in the

Unlike its predecessors, the REWIND trial was not aimed at uncovering cardiovascular safety of GLP-1RAs

In this episode and the accompanying feature, we invited a patient with lived experience to see if this worked in real life while discussing the potential mechanisms with a researcher.

doi: 10.1038/nature11450 101 RauM.RehmanA.DittrichM.GroenA

From the moment you place your order to the final results, our dedicated team of health coaches is there with you, guiding you through your journey and pointing you in the right direction to address any concerns

When the upper bound of the 2-sided 95% confidence interval falls between 1.3 and 1.8, a post-marketing safety trial will be required to document that the true CV risk does not exceed a 30% increase